ArticleHNO2026
[Comparison of cutaneous squamous cell carcinomas of the face and ear with and without external auditory canal involvement].
Article in HNO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn cutaneous squamous cell carcinoma (cSCC) of the auricle or external auditory canal entrance, involvement of the external auditory meatus (EAM) is associated with an unfavorable prognosis. The aim of this study was to evaluate oncologic outcomes as well as immunosuppressive comorbidities as potential risk factors.
methodsA total of 137 patients treated between 2007 and 2017 were included (31 cSCCs of the auricle or external auditory canal entrance with EAM involvement, 60 auricular cSCCs, 9 lip cSCCs, and 37 nasal cSCCs). Oncologic characteristics and immunosuppressive comorbidities were analyzed retrospectively.
resultsThe cSCCs with EAM involvement presented with significantly more advanced T and N stages than all other subgroups. Whereas EAM involvement was associated with a 1.2-fold increased risk of tumor recurrence (p = 0.016), advanced T and N stage were associated with a 1.8- and 2.5-fold increased risk of tumor-related death, respectively. After adjustment for T and N stage, the overall survival of patients with EAM involvement was comparable to that of patients with other tumor locations. Immunosuppressive comorbidities were identified in 25% of patients, most commonly diabetes mellitus, hematologic disorders, and a history of heart or kidney transplantation. However, Cox regression analysis revealed no significant association between immunosuppressive comorbidities and either recurrence-free or overall survival.
conclusionPatients with cSCC of the auricle or external auditory canal entrance involving the EAM presented with significantly more advanced T and N stages at diagnosis, underscoring the need for more aggressive treatment strategies, including consideration of adjuvant therapy. After adjustment for T and N stage, overall survival was comparable to that of other tumor locations, suggesting that the poorer prognosis associated with EAM involvement is primarily attributable to more advanced disease at presentation rather than to distinct tumor biology.
Indexed as
Identifiers
42752956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.